Last reviewed · How we verify
potassium losartan
potassium losartan is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Fifth Affiliated Hospital, Sun Yat-Sen University. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Diabetic nephropathy in patients with type 2 diabetes. Also known as: Kesiya, Losartan, Placebo.
Losartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Losartan is used to treat conditions such as hypertension, diabetes mellitus, and sleep apnea, as indicated by ClinicalTrials.gov. It is classified as an angiotensin receptor blocker (ARB), which is a type of non-ACEI/ARB intervention, according to ClinicalTrials.gov and ChEMBL.
At a glance
| Generic name | potassium losartan |
|---|---|
| Also known as | Kesiya, Losartan, Placebo |
| Sponsor | Fifth Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation and reduces sodium and water retention, thereby decreasing blood pressure and reducing cardiac workload. The potassium salt formulation provides the active losartan component while delivering potassium as the counterion.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Diabetic nephropathy in patients with type 2 diabetes
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
Key clinical trials
- The Effect of Losartan on Cephalexin (PHASE1)
- Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease (PHASE2)
- Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma (PHASE1)
- Losartan for Corneal Fibrosis (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- The COVID-RASi Trial (COVID-19) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- potassium losartan CI brief — competitive landscape report
- potassium losartan updates RSS · CI watch RSS
- Fifth Affiliated Hospital, Sun Yat-Sen University portfolio CI
Frequently asked questions about potassium losartan
What is potassium losartan?
How does potassium losartan work?
What is potassium losartan used for?
Who makes potassium losartan?
Is potassium losartan also known as anything else?
What drug class is potassium losartan in?
What development phase is potassium losartan in?
What are the side effects of potassium losartan?
What does potassium losartan target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Fifth Affiliated Hospital, Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Diabetic nephropathy in patients with type 2 diabetes
- Also known as: Kesiya, Losartan, Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing